bullish
Chugai Pharmaceutical (4519 JP): Emicizumab Gets PDUFA Data
243 Views27 Aug 2017 18:04
Chugai Pharmaceutical (4519 JP) announced on August 24th that the US FDA has accepted its Biologics License Application (BLA) for emicizumab (emi)...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 2-minute read)
Discussions
(Paid Plans Only)
Pelham Smithers Associates
Market Intel on Asian Tech with a Japan focus
Price Chart(Sign Up to Access)
- Chugai Pharmaceutical (4519 JP): Emicizumab Gets PDUFA Data27 Aug 2017
- Chugai – Positive Data for Emicizumab from HAVEN 219 Apr 2017
- Chugai Pharmaceutical-Exceptionally Productive In-House R&D Driving Strong Growth11 Feb 2017
- ACE910 (Emicizumab) – A Novel Factor VIII (FVIII) –Mimetic Bi-Specific Antibody25 Jan 2017
x